Physician profile
Carl E Kramer
NPI 1235512286
$12,782.70
in general payments reported to CMS, 2019-2025
14 companies · $4,831 in 2025
The $4,831 reported for 2025 was more than what 96% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,619 · 2020: $300 · 2021: $378 · 2022: $321 · 2023: $2,162 · 2024: $2,171 · 2025: $4,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,375 · Food and Beverage: $1,777 · Travel and Lodging: $1,012 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,375.00 |
| Food and Beverage | $1,777.20 |
| Travel and Lodging | $1,012.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valley Contax, INC. | $7,979.34 | 2019-2025 | |
| Coopervision INC. | $1,194.06 | 2020-2025 | Clariti Contact Lens, Myday Contact Lens, Onefit Contact Lens |
| Alcon Vision LLC | $1,176.74 | 2020-2025 | Air Optix, Total30, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $1,048.65 | 2019-2025 | Acuvue |
| Glaukos Corporation | $636.31 | 2023-2025 | Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem, Ce-Marked Kxla System |
| Bausch & Lomb Americas INC. | $215.08 | 2023-2025 | Infuse |
| Sun Pharmaceutical Industries INC. | $143.02 | 2025 | |
| Dompe US, INC. | $127.29 | 2024-2025 | Oxervate |
| Abbvie INC. | $112.17 | 2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $61.00 | 2021 | |
| Menicon America INC | $27.53 | 2024 | |
| Harrow Eye, LLC | $21.92 | 2024 | Flarex |
| Amgen INC. | $20.59 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $19.00 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.